Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK-Positive Lung Adenocarcinoma: A Case Report
{{output}}
Anaplastic lymphoma kinase (ALK) fusion genes are detected in approximately 3%-5% of non-small cell lung cancers (NSCLC). Alectinib and lorlatinib are ALK tyrosine kinase inhibitors with established efficacy; however, their adverse event profiles differ. We re... ...
